A Panel of TrpB Biocatalysts Derived from Tryptophan Synthase through the Transfer of Mutations that Mimic Allosteric Activation by Murciano-Calles, Javier et al.
A Panel of TrpB Biocatalysts Derived from Tryptophan Synthase 
through the Transfer of Mutations that Mimic Allosteric 
Activation
Javier Murciano-Callesa,b, David K. Romneya,b, Sabine Brinkmann-Chena, Andrew R. 
Bullera, and Frances H. Arnolda,*
aDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, 
California 91125, USA
Abstract
Naturally occurring enzyme homologs often display highly divergent activity with non-natural 
substrates. Exploiting this diversity with enzymes engineered for new or altered function, however, 
is laborious because the engineering must be replicated for each homolog. We demonstrate that a 
small set of mutations of the tryptophan synthase β-subunit (TrpB) from Pyrococcus furiosus, 
which mimic the activation afforded by binding of the α-subunit, has a similar activating effect in 
TrpB homologs with as little as 57% sequence identity. Kinetic and spectroscopic analyses 
indicate that the mutations function through the same mechanism, mimicry of α-subunit binding. 
From this collection of stand-alone enzymes, we identified a new catalyst that displays a 
remarkably broad activity profile in the synthesis of 5-substituted tryptophans, a biologically 
important class of compounds. This investigation demonstrates how allosteric activation can be 
recapitulated throughout a protein family to efficiently explore natural sequence diversity for 
desirable biocatalytic transformations.
TOC image
The tryptophan synthase enzyme complex is active toward a number of indole analogs. The β-
subunit (TrpB) performs the synthetically useful reaction, but requires the α-subunit to be fully 
active. We have transferred mutations from a re-activated TrpB variant from Pyrococcus furiosus 
into homologous TrpBs to generate a panel of stand-alone TrpB catalysts, one of which is 
especially useful for making 5-substituted tryptophans, an important biological motif.
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Tryptophan synthases (TrpSs) are α2β2 heterodimer complexes that catalyze the synthesis of 
tryptophan (1) from 3-indole-D-glycerol phosphate (IGP, 2) and L-serine (3, Figure 1a). 
TrpS also reacts with myriad indole analogs, providing a direct biocatalytic route to making 
tryptophan derivatives.[1] In such reactions, only the β-subunit (TrpB) performs catalysis 
(Figure 1b), but its activity is greatly diminished in the absence of the α-subunit (TrpA), 
limiting its utility as a biocatalyst.[2] Recently, we applied directed evolution to the β-subunit 
from Pyrococcus furiosus (PfTrpB) to identify mutations that emulate the effect of TrpA 
binding and imbue the β-subunit with high activity in isolation.[3] However, this stand-alone 
catalyst, PfTrpB0B2, exhibited poor levels of activity in the synthesis of 5-substituted 
tryptophans, a prevalent structural motif in bioactive natural products.[4] We hypothesized 
that if TrpB homologs could be activated by transferring the allostery-mimicking mutations 
identified in PfTrpB0B2, some of the resultant catalysts might have greater activity with 5-
substituted indoles.
The central challenge in enzyme engineering is to traverse the sequence space that separates 
a wild-type enzyme from its variant with novel functional properties. Instead of repeating 
the directed evolution to activate each new TrpB homolog, we decided to try to shortcut that 
effort by transferring beneficial mutations discovered in PfTrpB to different homologs. This 
would create a panel of TrpB enzymes, possibly with different substrate scopes or other 
useful properties for biocatalytic applications. Transfer of beneficial mutations to other, 
closely-related enzymes is widely used to improve properties, such as stability, but this 
approach assumes either that the effects of the mutations are independent and additive, as 
with thermostabilization by consensus design,[5] or at least that the protein context is shared 
(high sequence identity in the region of the mutation).[6] In an allosterically modulated 
enzyme such as TrpS, catalytic activity is increased by ligand (TrpA) binding at a location 
separate from the active site. Allosteric activation thus involves the participation of many 
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residues, even the entire protein, as well as the surrounding solvent.[7] Furthermore, residues 
that contribute to allosteric signalling are poorly conserved by evolution,[8] causing 
homologous proteins to develop different allosteric mechanisms.[9] It was thus uncertain 
whether mutations that mimic allostery in TrpS from one species would be generalizable to 
other homologs.
We selected three phylogenetically diverse TrpBs[10] to serve as the basis for new stand-
alone catalysts: the hyperthermostable enzymes from Archaeoglobus fulgidus (AfTrpB, 72% 
sequence identity to PfTrpB) and Thermotoga maritima (TmTrpB, 64% identity), and the 
mesophilic enzyme from Escherichia coli (EcTrpB, 57% identity).[11] We were especially 
interested in TmTrpB because its wild-type kcat is already four times that of PfTrpB.[12] 
Activation of EcTrpB would be desirable because it is adapted to a different temperature 
(37 °C versus 96 °C for PfTrpB), which may be useful for less stable substrates.
Previously, we observed that PfTrpB was a sluggish catalyst (Table 1, entry 1), but that 
variant PfTrpB0B2, which was engineered using three rounds of directed evolution, exhibited 
a 9-fold increase in kcat with an equivalent decrease in KM (Table 1, entry 2). We expressed 
and purified the three TrpB homologs and their corresponding 0B2 variants to test whether 
the activating mutations would produce a similar effect. Compared to AfTrpB (Table 1, entry 
3), the variant AfTrpB0B2 has a 7-fold higher kcat and 2-fold lower KM for indole (Table 1, 
entry 4).
The absorption spectrum of PLP changes as the cofactor passes through different states of 
the catalytic cycle (Figure 1b).[2a] Thus, the absorption spectrum of the enzyme under 
reaction conditions directly reflects the steady-state distribution of catalytic intermediates. 
Before the addition of Ser, AfTrpS, AfTrpB, and AfTrpB0B2 all display an absorbance peak 
at 412 nm (Figure 2), which corresponds to the absorbance of E(Ain). When Ser is added to 
AfTrpS, its spectrum exhibits a new λmax at 350 nm (Figure 2a), indicating that E(A-A) is 
prevalent in the steady state of the catalytic cycle for this enzyme. Conversely, AfTrpB lacks 
a λmax at 350 nm, but instead possesses an absorbance peak at 428 nm (Figure 2b), 
indicating that E(Aex1) is the most prevalent intermediate. The spectrum of AfTrpB0B2, on 
the other hand, is almost identical to that of AfTrpS, with a prominent λmax of 350 nm 
(Figure 2c). This behavior matches what we observed previously[3] and provides compelling 
evidence that the 0B2 mutations activate AfTrpB by the same mechanism as they did in 
PfTrpB, namely by mimicking the allosteric activation produced by binding of TrpA to 
TrpB.
The TmTrpB homolog (Table 2, entry 1) already contains the residue A321 in its native 
sequence. However, incorporation of the remaining five mutations from PfTrpB0B2 reduced 
the kcat to just 10% of the wild-type activity (Table 2, entry 2). To investigate whether a 
subset of these mutations could still be activating, we constructed a recombination library of 
the 0B2 mutations in TmTrpB and screened for activity with indole. Three mutations, P19G, 
I69V, and T292S, increased the activity with respect to wild type. The variant having all 
three mutations was most active, with an 8-fold increase in kcat (Table 2, entry 3). The 
T292S mutation by itself was also substantially activating, producing a 4-fold increase in 
kcat (Table 2, entry 4).
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As with AfTrpS and PfTrpS, the UV-vis absorption spectrum of TmTrpS exhibits a strong 
λmax at 350 nm under the reaction conditions. Once again, TmTrpB lacks this probative 
peak and instead exhibits the λmax at 428 nm that was observed for AfTrpB and PfTrpB. 
While all permutations of the three mutations (P19G, I69V, and T292S) led to improved kcat 
values (Figure S3), only the variants with T292S exhibited a λmax at 350 nm, equivalent to 
TmTrpS (Figure S4). The importance of the T292S mutation was also observed in PfTrpB, 
where this mutation alone restored the kcat of the isolated PfTrpB to that of the PfTrpS 
complex[3]. The effects of this conservative mutation were even more dramatic in TmTrpB, 
producing a kcat almost 3-fold higher than TmTrpS (Table 2, cf. entries 4 and 5).
Mutational activation of the most distant homolog, EcTrpB (57% identity), proved more 
challenging. The crucial Thr→Ser mutation was not possible for EcTrpB because EcTrpB 
already has Ser at this position (S297). Site-saturation mutagenesis confirmed that serine is 
the optimal residue at that position (Figure S5a). Unlike TmTrpB, recombination of the 0B2 
mutations in EcTrpB yielded no variants with enhanced activity and only a few with activity 
similar to wild type (Figure S5b).
The initial screening effort with PfTrpB[3] had also identified a variant with mutations 
M144T and N166D that was almost as active as PfTrpBT292S (Table 3, entry 1). These two 
residues, unlike T292, reside in the so-called communication (COMM)[2a] domain, which 
interfaces with TrpA and undergoes large conformational motions during the catalytic cycle. 
These residues are identical in the four homologs studied here and are almost universally 
conserved across all TrpBs (Figure S6). We hypothesized that the effects of mutations at 
these sites might also be transferrable. Upon making the equivalent mutations in EcTrpB, 
TmTrpB, and AfTrpB, we observed activation in all variants, with approximately 2- to 5-
fold increases in kcat (Table 3, entries 2 to 4).
We wished to verify that the proteins were still being activated by allosteric mimicry. UV-vis 
analysis of the steady-state distributions of intermediates upon addition of L-serine revealed 
that the double mutants of PfTrpB and EcTrpB still accumulated E(Aex1) rather than E(A-
A) (Figure S7a and d). However, the homologous double mutants of A. fulgidus and T. 
maritima showed shifted spectra, in which E(A-A) predominated (Figure S7b and c). These 
data suggest that the double mutation is also activating the enzymes through allosteric 
mimicry, but that it does not quite reach the activation generated by adding TrpA. This 
situation is reminiscent of the earlier evolution of PfTrp0B2, wherein the lone T292S 
mutation was insufficient to completely shift the UV-vis spectrum to E(A-A) without at least 
four additional mutations.[3]
In the pantheon of tryptophan-derived natural products, one can find substitution at every 
position on the indole moiety (Figure 3). Position 5, for example, is chlorinated by the 
halogenase PyrH, en route to pyrroindomycin B (6),[4a] and mono-oxygenated by tryptophan 
hydroxylase in the biosynthesis of serotonin (7) and melatonin (8).[4d] Such substituents 
have a profound effect on biological activity because they can mask sites of metabolic 
degradation and change the compound’s electronic properties. This, in turn, alters properties 
like solubility and creates new binding interactions through effects such as π-stacking and 
halogen bonding.[1b, 13] Halogens can also provide handles for further diversification of 
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biologically active compounds through cross-coupling reactions.[14] While biocatalytic 
routes to tryptophan derivatives tend to be inefficient and limited in substrate scope, TrpS 
can provide direct access to many of these products. Previously, however, 5-substituted 
indoles bearing anything larger than fluorine caused a substantial decrease in 
activity[1d, 1f, 15]. Furthermore, TrpS activity with electron-deficient indoles had not been 
explored.
One enzyme in our repertoire, TmTrpBM145T N167D, showed higher activity with 5-
bromoindole than even our most optimized catalyst, PfTrpB0B2 (Figure S8). To assess 
whether this was a general property of the catalyst, we compared the relative rates of 
TmTrpBM145T N167D to PfTrpB0B2 with a set of challenging 5-substituted indoles (Table 4). 
We then applied TmTrpBM145T N167D in reactions that were run to higher conversion in 
order to isolate and characterize the products.
With 5-chloroindole, the Tm variant exhibits a 3-fold rate enhancement compared to 
PfTrpB0B2 (Table 4, entry 1). Despite this improvement, the reaction still appeared to stall at 
about 85% conversion when the substrates were used in equal amounts, possibly due to 
competing decomposition of serine.[16] We overcame this limitation by using a small excess 
of serine, allowing us to obtain 5-chlorotryptophan in 94% isolated yield. PfTrpB0B2 has 
even greater difficulty with 5-bromoindole, but the Tm variant is almost six times as fast for 
this substrate, allowing us to obtain 5-bromotryptophan in 88% isolated yield (Table 4, entry 
2). These results compare favorably with previous reports, in which TrpS from Salmonella 
enterica was shown to form 5-chloro and 5-bromotryptophan in 61% and 26% yield, 
respectively[1f].
TmTrpBM145T N167D exhibits substantially faster rates, ranging from 2- to over 7-fold, with 
substrates that bear electron-withdrawing groups, such as nitro, cyano, formyl, and even 
boronate (Table 4, entries 3–6), representing a new substrate class in the TrpS literature. The 
reaction with 5-boronoindole is particularly interesting, as the catalyst must contend with 
competing proto-deborylation. Boronic acids can serve as handles for bio-orthogonal 
conjugation,[17] pH-sensitive delivery of therapeutics in vivo,[18] and substrates for cross-
coupling, complementing 5-halotryptophans, for which electron-deficient coupling partners 
lead to reduced yields.[19] Although the reactivity with these new substrates remains low, we 
believe that TmTrpBM145T N167D, which only has two mutations compared to six in 
PfTrpB0B2, is the ideal parent for further optimization.
PfTrpB0B2 already has excellent activity with substrates that bear electron-donating groups 
at the 5-position (e.g., hydroxy, methyl, and methoxy); nonetheless, TmTrpBM145T N167D 
delivers a 1.5-fold faster rate (Table 4, entries 7–9), which is helpful because such electron-
rich substrates are prone to aerobic oxidation. Thus, TmTrpBM145T N167D performs almost 
10,000 turnovers in just two hours, allowing the products to be isolated in high yield without 
the need for oxygen-free conditions.
By mining the wealth of activating mutations in PfTrpB, we have identified subsets that 
retain their effects when transferred into related enzymes, including those from different 
domains of life (archaea and bacteria). Importantly, spectroscopic data indicate that the 
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homologs are activated through the same mechanism as the PfTrpB variants, namely 
mimicking the effects of TrpA binding. By screening the resulting panel of activated TrpB 
homologs, we have identified a variant with broadly improved activity toward 5-substituted 
indoles, a substrate class that had proven problematic for all previous catalysts. The strategy 
used here could be applied to other TrpBs and exemplifies how the transfer of activating 
mutations to homologous enzymes can rapidly expand activity with non-native substrates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Native reaction mediated by TrpS and the catalytic cycle of TrpB. (a) TrpA degrades 2 
through retro-aldol cleavage to give indole (4) and D-glyceraldehyde (5). Substrate 4 then 
reacts with 3 to form 1. (b) TrpB contains a pyridoxal 5′-phosphate (PLP) cofactor bound as 
an internal aldimine, E(Ain), which covalently binds 3 as an external aldimine, E(Aex1). 
Subsequent deprotonation and dehydration form the amino-acrylate, E(A-A). Finally, 4 
reacts with E(A-A) to form 1.
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Figure 2. 
UV-vis absorption spectra of (a) AfTrpS, (b) AfTrpB, and (c) AfTrpB0B2 before (solid 
black) and after (dashed grey) addition of L-serine.
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Figure 3. 
Numbering of positions on the indole moiety of tryptophan and examples of natural products 
bearing substitution at position 5.
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Table 1
Kinetic parameters of the Pyrococcus furiosus and Archaeoglobus fulgidus TrpB wild-type enzymes and 0B2 
variants.[a]
Entry Enzyme
kcat
(s−1)
KM
(μM indole)
kcat/KM
(μM−1 s−1 indole)
1 PfTrpBWT 0.31 77 4.0
2[b] PfTrpB0B2 2.9 9 300
3 AfTrpBWT 0.074 12 6.0
4[c] AfTrpB0B2 0.51 4.8 110
[a]Assays conducted in potassium phosphate buffer (pH 8) at 75 °C for Pf and 60 °C for AfTrpB. See SI section 5.4 for experimental details. 
Standard errors are in Table S1.
[b]Contains the mutations P12L, E17G, I68V, F274S, T292S, and T321A.
[c]Contains the mutations P25L, P30G, I80V, L285S, T303S, and T321A.
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Table 2
Kinetic parameters of Thermotoga maritima TrpB variants and TrpS.[a]
Entry Enzyme
kcat
(s−1)
KM
(μM indole)
kcat/KM
(μM−1 s−1 indole)
1 TmTrpBWT 1.28 33 39
2 TmTrpB0B2 [b] 0.11 72 2.0
3 TmTrpBtriple [c] 9.8 26 380
4 TmTrpBT292S 5.8 25 230
5 TmTrpS 2.2 44 50
[a]Assays conducted in potassium phosphate buffer (pH 8) at 75 °C. See SI section 5.4 for experimental details. Standard errors are in Table S1.
[b]Contains the mutations P14L, P19G, I69V, L274S and T292S.
[c]Contains the mutations P19G, I69V, and T292S.
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Table 3
Kinetic parameters of Pyrococcus furiosus TrpBM144T N166D and its homologs.[a]
Entry Enzyme
kcat
(s−1)
KM
(μM indole)
kcat/KM
(μM−1 s−1 indole)
1 PfTrpBM144T N166D 0.83 42 20
2[b] EcTrpBM149T N171D 0.34 18 19
3 TmTrpBM145T N167D 3.3 32 100
4 AfTrpBM156T N178D 0.34 11 31
[a]Assays conducted in potassium phosphate buffer (pH 8) at 75 °C for Pf and Tm, 60 °C for Af, and 37 °C for EcTrpB. See SI section 5.4 for 
experimental details. Standard errors are in Table S1.
[b]EcTrpB has the following: kcat = 0.16 s−1; KM = 19 μM (indole); kcat/KM = 8 μM−1 s−1 (indole).
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Table 4
Synthesis of 5-substituted tryptophan derivatives with Thermotoga maritima TrpBM145T N167D[a]
Reaction with TmTrpBM145T N167D [a]
Entry X Relative rate vs PfTrpB0B2 Isolated yield (%)[b] Total turnovers[c]
1 Cl 3.0 93 9300
2 Br 5.6 88 4400
3 NO2 7.5 25 1250
4 CN 4.5 49 2450
5 CHO 1.9 32 1600
6 B(OH)2 1.8 38[d] 1900[d]
7 OH 1.4 93[d] 9300[d]
8 CH3 1.4 91 9100
9 OCH3 1.5 76 7600
[a]See SI section 6 for experimental details. Standard errors are in Table S2.
[b]
Reactions used either 2 equiv (entries 1–6) or 1.2 equiv (entries 7–9) of L-serine. Products isolated by chromatography with C-18 silica.
[c]
Extrapolated from isolated yield based on maximum theoretical turnover number.
[d]
Determined by 1H NMR based on an internal standard.
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